Compare FMX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMX | NTRA |
|---|---|---|
| Founded | 1890 | 2003 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1B | 45.3B |
| IPO Year | 1998 | 2015 |
| Metric | FMX | NTRA |
|---|---|---|
| Price | $123.54 | $337.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $113.17 | ★ $259.07 |
| AVG Volume (30 Days) | 484.8K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $10.20 | $18.08 |
| Revenue Next Year | $8.32 | $19.65 |
| P/E Ratio | $40.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $83.33 | $157.43 |
| 52 Week High | $141.47 | $337.12 |
| Indicator | FMX | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 72.33 |
| Support Level | $121.06 | $187.64 |
| Resistance Level | $125.71 | N/A |
| Average True Range (ATR) | 2.15 | 10.88 |
| MACD | 0.71 | 1.95 |
| Stochastic Oscillator | 90.79 | 100.00 |
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.